Could the 340B/HOPD rule ripple into ASC reimbursement?
Tenet Healthcare said on its July 24 Q2 earnings call it is still modeling how CMS’s July 2 proposed 2027 OPPS/ASC rule could affect its ASCs. CMS would cut 340B drug payments to hospitals, expand site-neutral outpatient categories, and raise a 340B offset conversion factor to 3% to recover $7.8B by 2029. Tenet projects USPI adjusted EBITDA of $2.16B to $2.22B in 2026.
How this was made
The 30-second read
Why it matters
Tenet is treating the 340B reallocation as potentially material and is still modeling how hospital outpatient reimbursement changes could transmit to ASC pricing, volume, and margins. The article also notes potential constraints on health system capital for ASC joint ventures.
Market read
This is a regulatory-policy transmission story from hospital outpatient reimbursement to ASC economics, with Tenet signaling materiality but no finalized financial impact yet.
What to watch
The article highlights legal basis uncertainty for parts of the proposal and excludes hospitals enrolled after Jan. 1, 2018, which could materially change the effective impact by hospital mix.
Background
CMS proposed changes in the 2027 Hospital Outpatient Prospective Payment System and ASC rule, including 340B drug payment cuts and site-neutral payment expansion, plus a faster recovery of $7.8B in prior non-drug offsets.
Ticker impact
Tenet said it is still modeling how CMSs proposed 340B cuts and site-neutral HOPD changes could affect its ASC reimbursement and economics.
Near-term stock reaction likely limited because the article is about modeling and a future CMS final rule, not new Tenet guidance.
The newest company-specific facts are Tenets comments on materiality and ongoing modeling, plus a stated full-year 2026 USPI EBITDA range, while the final CMS rule is not expected until Nov. 1.
Market effects
CMSs proposed 340B and site-neutral changes could reprice hospital outpatient economics and accelerate procedure migration to ASCs, affecting ambulatory expansion and joint-venture capital allocation.
Not specified; impacts are described as affecting roughly 3,500 hospitals and 6,400 ASCs nationwide.
Limited, as the proposals are US Medicare reimbursement policy.
Counterpoint
ASC volume migration may be less immediate than implied if hospitals adjust service lines, renegotiate partnerships, or if final CMS details differ from the proposal.
Key entities
- companyTenet Healthcare
Discussed modeling of CMSs proposed 340B and HOPD reimbursement changes and their potential ASC impacts on pricing, volume, and margin.
- companyUSPI
Presented as having strong recent results and a full-year 2026 adjusted EBITDA outlook range, described as insulated from hospital reimbursement dynamics.
- regulatorCMS
Proposed Medicare reimbursement changes affecting 340B drug payments, site-neutral outpatient services, and recovery of prior non-drug offsets.
